V
Vir Biotechnology Inc (VIR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$9.58
-0.38 (-3.82%)
Market Cap: $1.71B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vir Biotechnology Inc (VIR) Valuation Multiples
Vir Biotechnology (VIR) trades at 5.4x sales and 1.8x book value. Its P/S of 5.4x is below its 5-year median of 12.5x. Its forward P/E is 4.3x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 4.3x |
| Price to sales | 5.4x |
| Price to book | 1.8x |
| PEG | N/A |
| FCF yield | -8.7% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 5.4x | 12.5x | N/A |
| P/B | 1.8x | 1.2x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 2.1x in 2022 to 62.6x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.03 | N/A | 12.2x | 1.1x |
| 2024 | $7.34 | N/A | 13.4x | 0.9x |
| 2023 | $10.06 | N/A | 15.6x | 0.9x |
| 2022 | $25.31 | 6.6x | 2.1x | 1.6x |
| 2021 | $41.87 | 10.8x | 5.1x | 3.9x |
| 2020 | $26.78 | N/A | 40.3x | 4.8x |
| 2019 | $12.58 | N/A | 62.6x | 2.7x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VIR
What is VIR's forward P/E ratio?
Vir Biotechnology has a forward P/E ratio of 4.3x.
Is VIR stock overvalued?
GNG's valuation label for VIR is Fairly valued.
What is VIR's price to sales ratio?
Vir Biotechnology has a price to sales ratio of 5.4x.
VIR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts